Laboratoires HRA Pharma continued to dominate the France emergency contraception market in 2012, with a 72% value share. With more than a decade of presence in the French territory, its key product NorLevo enjoys strong brand recognition locally. Its closest substitute, Lévonorgestrel Biogaran, has the advantage of being 22% cheaper, at €6.07 per tablet, when NorLevo is sold at €7.41 for a single tablet. In a context of declining demand for emergency contraceptive pills, value sales of both brands declined in 2012.
With the exception of NorLevo and Lévonorgestrel Biogaran, all contraceptive pills/methods in France are delivered only under medical prescription. These two levonorgestrel-based OTC emergency contraception products are freely available (from chemists/pharmacies, family planning centres and nursing staff in colleges) to the younger female population who are under the majority age of 18 years; for women aged 18+, they are reimbursed at 65%. The more recent emergency contraception pill EllaOne (active ingredient ulipristal acetate) allows a longer time lag of 120 hours (compared with 72 hours for the two former pills), and has become popular since its acceptance for 65% reimbursement from late 2010. EllaOne is still currently a strict Rx emergency contraceptive pill in France.
The ongoing rapid adoption of new methods of contraception, and public initiatives (such as the gratuity for VPIs from 2013 in France), will negatively impact emergency contraception in France over the forecast period, with a negative constant value CAGR of 3% expected.
For more information on the France emergency contraception market, please click here: France emergency contraception market
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.